These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. Tillerson JL; Cohen AD; Philhower J; Miller GW; Zigmond MJ; Schallert T J Neurosci; 2001 Jun; 21(12):4427-35. PubMed ID: 11404429 [TBL] [Abstract][Full Text] [Related]
3. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Tillerson JL; Caudle WM; Reverón ME; Miller GW Exp Neurol; 2002 Nov; 178(1):80-90. PubMed ID: 12460610 [TBL] [Abstract][Full Text] [Related]
4. Relationships among rat ultrasonic vocalizations, behavioral measures of striatal dopamine loss, and striatal tyrosine hydroxylase immunoreactivity at acute and chronic time points following unilateral 6-hydroxydopamine-induced dopamine depletion. Grant LM; Barnett DG; Doll EJ; Leverson G; Ciucci M Behav Brain Res; 2015 Sep; 291():361-371. PubMed ID: 26026785 [TBL] [Abstract][Full Text] [Related]
5. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Tillerson JL; Caudle WM; Reverón ME; Miller GW Neuroscience; 2003; 119(3):899-911. PubMed ID: 12809709 [TBL] [Abstract][Full Text] [Related]
6. A novel skilled-reaching impairment in paw supination on the "good" side of the hemi-Parkinson rat improved with rehabilitation. Vergara-Aragon P; Gonzalez CL; Whishaw IQ J Neurosci; 2003 Jan; 23(2):579-86. PubMed ID: 12533618 [TBL] [Abstract][Full Text] [Related]
7. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway. Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. Cohen AD; Tillerson JL; Smith AD; Schallert T; Zigmond MJ J Neurochem; 2003 Apr; 85(2):299-305. PubMed ID: 12675906 [TBL] [Abstract][Full Text] [Related]
9. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350 [TBL] [Abstract][Full Text] [Related]
10. Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Balcioglu A; Zhang K; Tarazi FI Neuroscience; 2003; 119(4):1045-53. PubMed ID: 12831863 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. Lu JQ; Stoessl AJ Neuroscience; 2002; 112(2):261-6. PubMed ID: 12044444 [TBL] [Abstract][Full Text] [Related]
13. Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exacerbates [corrected] parkinsonian symptoms. Chao OY; Huston JP; von Bothmer A; Pum ME Neuroscience; 2011 Nov; 196():228-36. PubMed ID: 21888950 [TBL] [Abstract][Full Text] [Related]
14. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Aoi M; Date I; Tomita S; Ohmoto T Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110 [TBL] [Abstract][Full Text] [Related]
15. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. Haycock JW; Becker L; Ang L; Furukawa Y; Hornykiewicz O; Kish SJ J Neurochem; 2003 Nov; 87(3):574-85. PubMed ID: 14535941 [TBL] [Abstract][Full Text] [Related]
16. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine. Moroz IA; Peciña S; Schallert T; Stewart J Exp Neurol; 2004 Sep; 189(1):78-93. PubMed ID: 15296838 [TBL] [Abstract][Full Text] [Related]
17. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Srinivasan J; Schmidt WJ Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465 [TBL] [Abstract][Full Text] [Related]
18. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972 [TBL] [Abstract][Full Text] [Related]
19. Use-dependent behavioral and neurochemical asymmetry in MPTP mice. Caudle WM; Tillerson JL; Reverón ME; Miller GW Neurosci Lett; 2007 May; 418(3):213-6. PubMed ID: 16603316 [TBL] [Abstract][Full Text] [Related]
20. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Kemmerer ES; Desmond TJ; Albin RL; Kilbourn MR; Frey KA Exp Neurol; 2003 Sep; 183(1):81-6. PubMed ID: 12957491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]